Pages that link to "Q28476301"

The following pages link to NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance (Q28476301):

Displaying 23 items.

• Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. (Q33750171) (← links)
• A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells (Q34977187) (← links)
• RETRACTED: Vulnerability of glioblastoma cells to catastrophic vacuolization and death induced by a small molecule (Q35127614) (← links)
• Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer (Q35587385) (← links)
• NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. (Q35851832) (← links)
• Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis (Q35930414) (← links)
• Cell-based high-throughput screens for the discovery of chemotherapeutic agents (Q36071888) (← links)
• Antiinfectives targeting enzymes and the proton motive force. (Q36419761) (← links)
• PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells (Q36738640) (← links)
• Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells (Q36843815) (← links)
• Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats (Q36881996) (← links)
• Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance (Q37696336) (← links)
• Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression (Q37707677) (← links)
• Cell death assays for drug discovery (Q37848054) (← links)
• Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. (Q37937579) (← links)
• Investigational ABC transporter inhibitors (Q38001734) (← links)
• Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer (Q38819410) (← links)
• NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo (Q38910267) (← links)
• Gambogic acid as a non-competitive inhibitor of ATP-binding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATP-binding cassette transporter B1 protein degradation (Q39320594) (← links)
• Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles (Q39547412) (← links)
• Molecular insight into conformational transmission of human P-glycoprotein. (Q44488182) (← links)
• Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. (Q47129596) (← links)
• Novel Quinoline Compound Derivatives of NSC23925 as Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance (Q92542448) (← links)